- Home
- CRIS vs MDCX Comparison
CRIS vs MDCX Comparison
Compare CRIS & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.13
Company Overview
Basic Information| Metric | CRIS | MDCX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 15.9M |
| IPO Year | 2000 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRIS | MDCX |
|---|---|---|
| Price | $1.13 | $0.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.00 | $14.50 |
| AVG Volume (30 Days) | 139.0K | ★ 5.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.18 | $0.15 |
| 52 Week High | $6.74 | $3.05 |
Technical Indicators
Market Signals| Indicator | CRIS | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 23.56 | 25.42 |
| Support Level | $0.80 | N/A |
| Resistance Level | $1.21 | $0.36 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 6.00 | 5.11 |
Price Performance
Historical Comparison CRIS
MDCX
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.